PETROSCRAP.COM

Skinvisible Submits Invisicare Formulation for FDA Orphan Drug Designation
LAS VEGAS — Skinvisible, Inc. today announced the submission of an application for an Orphan Drug Product Designation for the Company’s product formulated with Invisicare to treat Netherton Syndrome, a sub-type of ichthyosis disease.

Read more on GlobeNewswire via Yahoo! Finance

This entry was posted on Thursday, March 24th, 2011 at 1:34 pm and is filed under Polymer News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.